Updated: February 11th at 2:30pm
Humana executives told investors Tuesday morning that the company is focusing on operational excellence as it attempts to navigate choppy financial water.
CEO Jim Rechtin said in a call to the company's revenues that Humana still doesn't provide a prospect until 2026, and there are plenty of unknowns that need to be combined before fully outlines plans for next year. there is. For one thing, the Centers for Medicare & Medicaid Services have released a proposal for an annual pre-release notice to administer private Medicare plans, but the reimbursement rate has not been finalized.
Furthermore, star ratings for the Medicare Advantage program remain a major concern. Humana is one of many insurers involved in the recent litigation against CMS against the CMS, and scored far lower overall for payers.
The Humana team focuses on what it can control in efforts to promote clinical excellence and in an effort to promote “efficient back offices” that will create two cornerstones for the strategy to advance. I stated. The work, he said, creates a foundation for successfully dealing with challenges like regulatory changes.
“When we do that, it leads us to a place where we can reach a sustainable, compelling and competitive place in the market,” says Rechtin.
Celeste Mellet, the chief financial officer who played his role on January 11, said “Looking the Corner” to predict headwinds as the company is working to improve its approach to multi-year planning. He said it could improve. It also allows the team to become more responsive when the team needs to make trade-offs, she said.
“We need to be ruthless about stopping things that aren't driving better results for our members and stopping better returns for our shareholders,” Mellett said.
Humana recorded a loss of $693 million in the fourth quarter of 2024, showing a marked increase from a loss of $541 million in the same period last year. Revenue Report It was released on Tuesday morning.
The company also halved its full-year profit for 2024 compared to 2023, recording $1.2 billion. Humana won $2.5 billion in profit in 2023.
Revenues rose both in the fourth quarter and the full year, according to the report. Revenue for the fourth quarter was $29.2 billion, up from $26.5 billion in the fourth quarter of 2023. Humana earned $117.8 billion in full-year revenue for 2024, compared to $106.4 billion in 2023.
According to Zacks Investment Research, the results surpassed Wall Street's expectations for both revenue and revenue.
“I was pleased with Humana's solid finish this year, reaffirming our outlook for 2025,” said Jim Letchin, CEO of Humana. “We are confident in our long-term strategy and 2025 will be an important step to return to our persuasive, normalized margins.”
According to the report, Humana has reaffirmed that its 2025 performance will be on par with 2024. Insurance companies expect to make $16.25 per share per year, and estimates that closing certain low-performance markets will result in the loss of around 550,000 Medicare Advantage (MA) members.
The company said it had a quarterly healthcare loss rate of 91.9%, which was consistent with its expectations. Humana said that the ongoing trends on rising utilization increased MLR, but offset some of those effects through its profit design.
The report added that increasing MA and Medicaid registrations tend to increase utilization and costs.
The insurance company had 16.5 million medical members as of the fourth quarter, including 8.5 million in all Medicare products.
